Axela Inc.

Presenter: Rocky Ganske, President & CEO

Company Information

Company Type: Select One

Development Stage: Select One

Company Profile

Axelas provides a powerful new approach to DNA, RNA and protein analysis that will revolutionize multiplex biomarker testing in clinical research and diagnostics. Axelas commercial research products significantly improve the amount and quality of information derived from traditional assays. This approach shortens time to result, greatly simplifies multiplexing and provides access to unique categories of markers that form a pipeline of future diagnostic offerings. Axela operates from its ISO 13485 certified facilities in Toronto and its major investor is VenGrowth Private Equity Partners Inc.

Presenter Bio

Rocky Ganske has over 25 years of experience in the medical diagnostics and life science fields, with a broad background in management, operations, science and regulatory affairs. Prior to joining Axela Inc. in 2003, he was Chief Operating Officer at Third Wave Technologies (TWTI), where he helped transform the company from one with great technology, into one operating at full commercialization through to an IPO on the NASDAQ. Prior to Third Wave Mr. Ganske worked at Becton Dickinson for 18 years in operational and regulatory management roles.

Contact

Axela Inc.
480 University Ave Suite 910
Toronto
ON, Canada
M5G 1V2

ph: 416-260-9150 x2251
fx: 416-260-9255

www.axela.com
rganske@axela.com